HSD17B13 and metabolic dysfunction-associated steatotic liver disease: Thus, HSD17B13 appears to be a driver of increased hepatic triglyceride storage and phospholipid remodelling, likely via increased Cept1 and Cd36 expression, and may explain at least part of the mechanism of its biological function and role in MASLD.